Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

Sanofi (SASY.PA) has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.
Sanofi did not disclose the financial terms of the deal. The agreement, which still needs to be finalized, will resolve most of the lawsuits against the French pharmaceutical company in U.S. state courts, with the exception of Delaware where the majority of the cases are pending.